For citizens

For companies

For medical specialists

PRAC recommends further measures to minimise risk of blood vessel blockage with Iclusig PRAC recommendations to be considered by CHMP for final opinion

The PRAC has completed a review of the benefits and risks of Iclusig (ponatinib), a medicine used for the treatment of leukaemia (cancer of the white blood cells). The aim of this review was to examine the risk of blood clots or blockage of the arteries or veins and to assess whether further measures were needed to minimise this risk.

More information

Copyright © 2017 Bulgarian Drug Agency.
All Rights Reserved.